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Summary
Enhancers, critical determinants of cellular identity, are commonly identified by correlative 
chromatin marks and gain-of-function potential, though only loss-of-function studies can 
demonstrate their requirement in the native genomic context. Previously we identified an erythroid 
enhancer of BCL11A, subject to common genetic variation associated with fetal hemoglobin 
(HbF) level, whose mouse ortholog is necessary for erythroid BCL11A expression. Here we 
develop pooled CRISPR-Cas9 guide RNA libraries to perform in situ saturating mutagenesis of 
the human and mouse enhancers. This approach reveals critical minimal features and discrete 
vulnerabilities of these enhancers. Despite conserved function of the composite enhancers, their 
architecture diverges. The crucial human sequences appear primate-specific. Through editing of 
primary human progenitors and mouse transgenesis, we validate the BCL11A erythroid enhancer 
as a target for HbF reinduction. The detailed enhancer map will inform therapeutic genome 
editing. The screening approach described here is generally applicable to functional interrogation 
of noncoding genomic elements.
Enhancers are classically described as distal genetic elements that positively regulate gene 
expression in an orientation-independent manner in ectopic heterologous gain-of-function 
expression experiments
1
. These elements coordinate when, where, and how genes are 
expressed. Enhancer sequences bind transcription factors and are correlated with specific 
chromatin features including reduced DNA methylation, characteristic histone 
modifications, heightened chromatin accessibility, long-range promoter interactions, and 
bidirectional transcription. Recent chromatin mapping has demonstrated the abundance of 
distal regulatory elements bearing an enhancer signature
2–4.
The biological importance of enhancers is underscored by gene expression studies showing 
the predictive power of enhancer profile on lineage-specific programs
5–7. Highly marked 
and clustered enhancers (e.g. so-called strong, stretch, or super-enhancers) are particularly 
suggestive of cellular identity and may help to infer lineage-specific regulatory factors
8–10. 
Genome-wide association studies reveal enrichment of trait-associated variants in sequences 
bearing lineage-restricted enhancer signatures
4,8,11,12. Enhancers display signs of 
evolutionary constraint as well as heightened turnover with evidence of positive 
selection
13–16.
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Despite their importance, enhancers are typically defined by criteria unrelated to in situ 
functional requirement. Advances in putative enhancer mapping, as well as large-scale 
oligonucleotide synthesis, facilitate enhancer reporter assays on a massively parallel scale, 
allowing a systematic evaluation of the functional significance of enhancer sequences
17,18. 
Nonetheless, ectopic heterologous enhancer assays cannot address the necessity of an 
element in its native chromatin environment. The growing appreciation of the nonrandom 
distribution of distal elements both with respect to the linear genome and within the three-
dimensional nuclear environment emphasizes the importance of studying enhancers by 
perturbing their endogenous condition
10,19.
Insightful observations have been made by mutagenizing enhancers using traditional 
molecular genetic approaches
20,21. However the low throughput of these classical methods 
constrains their widespread application. Furthermore the elevated turnover of many enhancer 
sequences between species may limit the ability to derive conclusions from nonhuman 
organisms regarding human gene regulation. Advances in genome editing technology make 
practical the facile modification of the human genome
22,23. High-throughput Cas9-mediated 
functional genomics studies have revealed novel genes required for various biologic 
processes
24–27. Genome editing is likewise suitable for the study of non-coding genetic 




Recently we observed that common genetic variants associated with HbF (α2γ2) level and β-
hemoglobin disorder clinical severity mark an adult developmental stage- and erythroid-
lineage specific intronic enhancer of BCL11A
28
, a validated repressor of HbF and 
therapeutic target for β-hemoglobin disorders
28,31–33. This composite human enhancer is 
composed of three DNase I hypersensitive sites (DHSs), termed h+55, h+58, and h+62, 
based on distance in kilobases from the transcriptional start site (TSS)
28
. The most highly 
trait-associated haplotype is defined by two SNPs, rs1427407 within h+62 and rs7606173 
within h+55 (Extended Data Fig. 1a). Previously we showed that this enhancer possessed 
ectopic erythroid-restricted, adult-stage-specific enhancer activity
28
. Moreover, the mouse 
ortholog of the composite enhancer, defined by primary sequence homology, shared 
erythroid enhancer chromatin signature, and syntenic position relative to coding sequences, 
was shown to be required for BCL11A expression and embryonic globin gene repression in 
a mouse erythroid cell line but dispensable in a mouse B-lymphoid cell line
28
.
To evaluate the requirement for human BCL11A enhancer sequences, we utilized HUDEP-2 
cells, an immortalized human CD34+ hematopoietic stem and progenitor cell (HSPC)-
derived erythroid precursor cell line that expresses BCL11A and predominantly β- rather 
than γ-globin
34
. We used the clustered regularly interspaced palindromic repeat (CRISPR)-
Cas9 nuclease system to generate clones of HUDEP-2 cells with deletion of the 12-kb 
BCL11A composite enhancer by introduction of a pair of chimeric single guide RNAs 
(sgRNAs). Enhancer deletion resulted in near complete loss of BCL11A expression and 
induction of γ-globin and HbF protein to similar levels as cells with BCL11A knockout (Fig. 
1a-c), consistent with the possibility that these sequences could serve as targets for 
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therapeutic genome editing for HbF reinduction for the β-hemoglobinopathies
35
. Although 
targeted deletions by paired double strand breaks (DSBs) may be achieved by genome 
editing, competing genomic outcomes include local insertion/deletion (indel) production at 
each cleavage site as well as inversion of the intervening segment
22,23,36–38.
Tiled pooled enhancer editing in situ
We hypothesized that composite enhancers may be composed of a functional hierarchy with 
essential and dispensable constituent components. A functional hierarchy might enable 
enhancer disruption by a single DSB at a critical region followed by nonhomologous end 
joining (NHEJ) repair with indels. In fact, the hypothesis that a prevalent mechanism of trait 
associations is enhancer variation rests on the premise that single nucleotide changes 
themselves may substantively modulate enhancer function. Therefore we reasoned that a 
tiling set of sgRNAs could uncover critical enhancer regions by disruption of nearly all 
sequences within an enhancer based on the typical outcome of Cas9 cleavage and NHEJ 
repair, an indel spectrum with frequent deletions of up to 10 bp from the cleavage 
position
22,23,36,38,39.
We designed all possible sgRNAs within the human BCL11A composite enhancer DHSs 
(Fig. 1d, e) as restricted only by the presence of the SpCas9 NGG protospacer adjacent motif 
(PAM), which restricts cleavage at an average 1/8 frequency at each genomic position
22,39. 
The NGG PAM restricted sgRNAs had a median gap between adjacent genomic cleavages of 
4 bp and 90th percentile of 18 bp (Fig. 1f), which suggested that this strategy could approach 
saturation mutagenesis in situ. We included nontargeting sgRNAs as negative controls as 
well as sgRNAs tiling exon-2 of BCL11A as positive controls (Fig. 1e). The library was 
successfully cloned to a lentiviral vector. The basic experimental schema was to transduce 
HUDEP-2 cells with the lentiviral library at low multiplicity such that nearly all selected 
cells contained a single integrant (Fig. 1d). Following expansion, differentiation, sorting by 
HbF level, genomic DNA isolation, and deep sequencing of integrated sgRNAs, an HbF 
enrichment score was calculated for each sgRNA by comparing its representation in HbF-
high and HbF-low pools (see Supplementary Information and Extended Data Fig. 2 for 
additional technical details).
We mapped the HbF enrichment score of each sgRNA to its predicted position of genomic 
cleavage (Fig. 2a). The majority of enhancer targeting sgRNAs showed no significant 
enrichment or depletion from the HbF-high pool. The enriching sgRNAs colocalized to 
discrete genomic positions. For example, we observed a cluster of sgRNAs at h+62 with 
modest enrichment, a cluster at h+55 with moderate enrichment (as well as adjacent clusters 
with depletion), and a cluster at h+58 with marked enrichment. Of note, we observed 10 
sgRNAs at h+58 with cleavage positions within 42 bp each with HbF enrichment scores 
exceeding 0.99, the median enrichment score of BCL11A exon-2 targeting sgRNAs.
Exon-2 targeted sgRNAs showed a linear correlation between HbF enrichment and cellular 
dropout, suggesting sgRNAs that result in complete knockout of BCL11A lead to a reduced 
rate of cell accumulation inseparable from HbF derepression (Fig. 2b). In contrast, the 
sgRNAs at h+58 associated with marked HbF enrichment showed blunted impact on dropout 
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(Fig. 2b). This finding could be consistent with a low residual level of BCL11A adequate to 
promote cellular accumulation but inadequate to suppress HbF.
To corroborate these findings, we introduced two sgRNAs to the HUDEP-2/Cas9 cells to 
produce targeted deletion or inversion clones
36
. Deletion of h+58 phenocopied deletion of 
the composite enhancer and deletion of h+55 had moderate effect (while deletion of h+62 
showed a nonsignificant trend towards a modest effect), consistent with the magnitude of 
top-scoring and colocalizing sgRNAs from the screen (Fig. 2a, c-e). Inversion of the h+58 or 
h+55 sites had no significant effect on gene expression, demonstrating that the BCL11A 




To validate the findings from the HUDEP-2 cells, the top-scoring enhancer targeting sgRNA 
from the screen (#1621 at h+58) was tested in primary human erythroblasts by lentiviral 
transduction of human CD34+ HSPCs exposed to ex vivo erythroid culture conditions. 
Consistent with the screen results, sgRNA-1621 resulted in downregulation of BCL11A 
expression and corresponding upregulation of γ-globin expression and increase in HbF+ 
cells (Fig. 2f-h). Notably, sgRNA-1621 did not alter surface marker profile, enucleation 
frequency, or cellular morphology (Extended Data Fig. 3c). Together these results suggest 
proof-of-principle of an individual sgRNA targeting a noncoding element for therapeutic 
genome editing of β-hemoglobin disorders.
Primate-specific enhancer sequences
We applied a hidden Markov model (HMM) to the sgRNA enrichment score data to infer 
functionally important sequences within each DHS (Extended Data Fig. 4a). This model 
defined three functional states, Active, Repressive, and Neutral, based on likelihood to 
encompass sequences that positively, negatively, and neutrally regulate target gene 
expression, respectively. The model identified functional states within each DHS (Fig. 3a-c). 
At each of the three DHSs, the Active states were precisely located at regions with the 
highest degree of DNase I sensitivity.
The overall sequence conservation at the h+58 Active region appears both less intense and 
less distinct from flanking sequences as compared to those of h+62 and h+55 (Fig. 3a-c). 
The top-scoring sgRNAs in the screen colocalize to 42 bp within h+58 (Fig. 4, Extended 
Data Fig. 5b). The third-highest scoring enhancer-targeted sgRNA (sgRNA-1617) mapped 
directly onto an apparent GATA1 motif, though below a genome-scale significance threshold 
(P = 3.74 × 10-4). The mouse orthologous sequence has a GATA1 motif P-value only 
modestly higher than the human (p = 4.33 × 10-4). This GATA1 motif appears to have 
relatively high vertebrate conservation, with exact human sequence identity in rabbits, pigs, 
dogs, and elephants. The top-scoring sgRNA (sgRNA-1621) mapped to a position 15 bp 
from this GATA1 motif (Fig. 4). An additional four sgRNAs mapping between sgRNA-1621 
and 1617 each had substantially elevated HbF enrichment scores. Underlying these sgRNAs 
were additional predicted motifs (i.e. RXRA, EHF, ELF1, and STAT1). Although these 
sequences showed a high level of conservation among primates, they showed high 
degeneracy among nonprimate vertebrates (Fig. 4).
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We tested the pattern of mutations observed upon treatment of cells with either sgRNA-1621 
or sgRNA-1617 by deep sequencing. Each of these sgRNAs is sufficient to substantially 
induce HbF in human erythroid cells (Fig. 2h; Extended Data Fig. 3a, b). We sorted cells 
exposed to Cas9 and these sgRNAs into HbF-high and HbF-low pools. We determined the 
indel spectrum in each population by deep sequencing (Extended Data Fig. 4b). As expected 
we observed indels clustering around the predicted cleavage positions. By comparing the per 
nucleotide indel ratio between cells from the HbF-high and HbF-low pools, we calculated a 
relative indel enrichment across the sequencing amplicon. Notably both sgRNAs yielded 
maximal HbF indel enrichment not precisely at the expected cleavage position but offset at 
shared intervening sequences (Fig. 4). These sites of maximal HbF mutation enrichment 
mapped to 7 bp directly overlapping predicted motifs (Fig. 4). Taken together, these data 
suggest that a conserved GATA1 motif scoring below the prediction threshold adjacent to 
primate-specific sequences form the core of an enhancer essential for human erythroid 
BCL11A expression and HbF repression.
Mouse enhancer dissection
To test functional conservation of the BCL11A enhancer, we examined the orthologous 
mouse Bcl11a enhancer in greater detail. Erythroid DNase I sensitivity is only observed at 
those sequences homologous to h+55 and h+62 and not h+58 (Extended Data Fig. 6a), 
consistent with the reduced sequence homology within the h+58 Active region (Fig. 3a-c). 
We performed a pooled CRISPR enhancer saturating mutagenesis screen in MEL 
εy:mCherry reporter cells, similar to the human screen described above (Extended Data Fig. 
6, 7; Supplementary Information).
Upon mapping the sgRNA cleavage positions to the genome, we again observed that the 
majority of enhancer targeting sgRNAs demonstrated no significant εy enrichment or 
depletion. We observed colocalization of sets of sgRNAs with εy enrichment (Fig. 5a). 
There was a similar complex pattern at the m+55 ortholog as at h+55, with adjacent regions 
with enriching and depleting sgRNAs from the high-εy:mCherry pool at the DHS core. At 
the m+58 ortholog we did not observe any evidence of εy enriching or depleting sgRNAs. At 
the m+62 ortholog there was a marked peak, with five sgRNAs with εy enrichment scores 
exceeding 1.30, the median enrichment score of Bcl11a exon-2 targeting sgRNAs (Fig. 5a). 
This potent impact of the m+62 ortholog was in contrast to the modest impact of individual 
sgRNAs or DHS deletion at h+62.
We used pairs of sgRNAs in the presence of Cas9 to produce MEL clones with deletions of 
various substituent elements at the Bcl11a enhancer (Fig. 5b). Deletion of the DNase-
insensitive m+58 ortholog had no apparent effect on BCL11A expression consistent with the 
pooled screen result. Deletion of the m+55 ortholog led to an approximately two-fold 
reduction in BCL11A expression (mean residual level 49%, p<0.0001), whereas deletion of 
the m+62 ortholog approached deletion of the entire composite enhancer in terms of 
reduction in BCL11A expression (mean residual levels of 8% (p<0.0001) and 6% 
(p<0.0001) respectively, Fig. 5b; also see Supplementary Information and Extended Data 
Fig. 8, 9). In addition, clones in which the m+62 ortholog was inverted showed no change in 
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BCL11A expression, suggesting that the mouse, like the human, enhancer functions 
independent of orientation in situ (Fig. 2c-e; 5b).
Erythroid-restricted function in vivo
To substantiate the importance of the m+62 ortholog for BCL11A expression and to validate 
BCL11A enhancer disruption as a therapeutic strategy, we generated mice deficient for the 
Bcl11a m+62 ortholog. We used the same Cas9 and paired sgRNA deletion strategy in 
mouse embryonic stem cells, from which we derived mice with germline transmission of the 
enhancer deletion. Previous studies have demonstrated essential roles for Bcl11a in 
structural development of the central nervous system and B-lymphopoiesis
40–42. Strikingly, 
unlike conventional Bcl11a knockouts, which die hours after birth, m+62 ortholog deletion 
mice were born healthy at expected Mendelian ratios (Extended Data Fig. 10a). The m+62 
ortholog deletion mice also showed normal frequencies of B-cell progenitors in the fetal 
liver and mature B-lymphocytes in the adult peripheral blood (Extended Data Fig. 10b, c). 
Other hematopoietic lineages were also observed at wild-type frequencies (Extended Data 
Fig. 10c). BCL11A expression was unperturbed in the brain or sorted B cell precursors from 
E16.5 embryos (Extended Data Fig. 10d). In contrast, there was substantial reduction in 
BCL11A levels in sorted E16.5 erythroid precursors (26% residual, P<0.05; Extended Data 
Fig. 10d).
The m+62 ortholog deletion mice were bred to mice transgenic for the human β-globin 
cluster (β-YAC) to model the role of BCL11A in hemoglobin switching
43
. Unlike its fetal-
stage expression in humans, in the mouse fetal liver transgenic human γ-globin is subject to 
intense repression (like an embryonic globin). Bcl11a is required for this early murine 
silencing of transgenic γ-globin at E14.5, although even in the absence of Bcl11a, γ-globin is 
ultimately repressed
32,33. Fetal livers were evaluated between days E12.5 and E18.5 to 
monitor hemoglobin switching. Repression of human γ-globin and activation of human β-
globin was markedly delayed in the m+62 ortholog deleted mice (Fig. 5c). Heterozygous 
mice showed an intermediate γ-globin derepression phenotype, underscoring the dose-
dependent inverse relationship between BCL11A and HbF level. These results indicate that 
targeting the erythroid enhancer of BCL11A in vivo results in erythroid-specific disruption 
of BCL11A expression and relaxed repression of γ-globin, unaccompanied by the obvious 
neurologic and immunologic toxicities seen in the BCL11A conventional knockout context.
Discussion
We employed a novel application of CRISPR-Cas9 genome editing, saturating mutagenesis 
of noncoding elements in situ, to provide important insight into the organization and 
function of the BCL11A erythroid enhancer. Traditional tests of enhancer function rely on 
ectopic heterologous reporter assays and/or correlative biochemical features. Genome 
editing allows facile evaluation of the requirement of enhancer sequences within their 
endogenous chromatin context for appropriate gene regulation. As shown here, high-
resolution high-throughput pooled tiling sgRNA screening reveals underlying enhancer 
sequence requirements approaching nucleotide resolution. A limitation to the resolution of 
this approach is the availability of NGG PAM sequences in a given region. We did not 
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observe efficient editing by SpCas9 with NAG restricted sgRNAs (Extended Data Fig 2f, 6i). 
Recent studies have identified Cas9 orthologs and variants restricted by alternate PAM 
sequences, each capable of efficient genome editing
44–46. This increased targeting range of 
Cas9 could allow increased resolution for in situ mutagenesis, particularly at sequences with 
paucity of NGG motifs. Alternatively, approaches reliant on homology-directed repair
47 
could offer nucleotide resolution functional mutagenesis of noncoding sequences, though 
issues of efficiency, fidelity, and quantitative sensitivity would need to be considered. We 
suggest that our tiled pooled CRISPR screening approach could be readily adapted to the 
functional interrogation of numerous noncoding genomic elements.
In addition, these data demonstrate that apparent sequence conservation at the BCL11A 
enhancer masks underlying functional divergence. The mouse and human BCL11A 
erythroid composite enhancers share primary sequence homology, an erythroid enhancer 
chromatin signature, and syntenic intronic position relative to coding sequences. Moreover, 
both are required for erythroid expression of BCL11A and repression of embryonic/fetal 
globin genes. However, our high-resolution CRISPR mutagenesis analysis reveals 
divergence in the architecture of these enhancers. Of note, human BCL11A enforces the γ- 
to β-globin developmental switch around the time of birth. The timing and nature of these 
switches and the globin genes themselves are distinct in primates as compared to nonprimate 
vertebrates that only exhibit a mid-gestation embryonic to adult switch
48
. Therefore it would 
seem plausible that critical regulatory mechanisms at BCL11A might differ between species 
(also see Supplementary Information).
The hemoglobin disorders represent one of the most common Mendelian inherited human 
conditions. The level of HbF is a key modifier of clinical severity of these diseases and 
BCL11A is the chief regulator of HbF level
48
. Natural occurring genetic variation at the 
BCL11A enhancer is well-tolerated and associated with HbF level and β-hemoglobin 
disorder clinical severity. The work presented here offers a framework for therapeutic 
genome editing of the BCL11A enhancer for β-hemoglobin disorders. Enhancer disruption 
by individual sgRNAs in primary erythroid precursors results in substantial HbF induction. 
This approach may mitigate erythroid-specific growth disadvantages of complete BCL11A 
loss (Fig. 3b). Furthermore erythroid enhancer disruption may spare BCL11A expression 
and function in nonerythroid contexts, such as B-lymphopoiesis (Extended Data Fig 10b-d). 
A challenge for the field is that it is not yet possible to accurately model HbF repression 
experimentally. However, individuals haploinsufficient for BCL11A due to microdeletions 
exhibit marked neurologic deficits, and elevated HbF beyond that seen in homozygotes for 
high-HbF common enhancer haplotypes
49,50. Taken together, these data suggest that 
perturbation of critical sequences within the BCL11A enhancer defined here may result in 
HbF levels exceeding a clinical threshold required to ameliorate the β-hemoglobin disorders.
Methods
Generation of genomic deletions in HUDEP-2 cells
HUDEP clone 2 (HUDEP-2), was utilized as previously described
34
. HUDEP-2 cells were 
expanded in StemSpan SFEM (Stem Cell Technologies) supplemented with 10-6 M 
dexamethasone (Sigma), 100 ng/mL human stem cell factor (SCF) (R&D), 3 IU/mL 
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erythropoietin (Amgen), 1% L-glutamine (Life Technologies), and 2% penicillin/
streptomycin. 1 μg/mL doxycycline (Sigma) was included in the culture to induce 
expression of the human papilloma virus type 16 E6/E7 genes
34
. HUDEP-2 cells were 
differentiated in Iscove's Modified Dulbecco's Medium (IMDM) (Life Technologies) 
supplemented with 330 μg/mL holo-transferrin (Sigma), 10 μg/mL recombinant human 
insulin (Sigma), 2 IU/mL heparin (Sigma), 5% human solvent detergent pooled plasma AB 
(Rhode Island Blood Center), 3 IU/mL erythropoietin, 100 ng/mL human SCF, 1 μg/mL 
doxycycline, 1% L-glutamine, and 2% penicillin/streptomycin.
Tandem sgRNA lentiviruses were transduced into HUDEP-2 with stable Cas9 expression 
(Supplementary Table 1). Bulk cultures were incubated for 7-10 days with 10 μg/mL 
blasticidin and 1 μg/mL puromycin selection to allow for editing. Then bulk cultures were 
plated clonally at limiting dilution. 96 well plates with greater than 30 clones per plate were 
excluded to avoid mixed clones. After approximately 14 days of clonal expansion, genomic 
DNA was extracted using 50 μL QuickExtract DNA Extraction Solution per well 
(Epicentre). Clones were screened for deletion by conventional PCR with one PCR reaction 
internal to segment to be deleted (‘non-deletion band’) and one gap-PCR reaction across the 
deletion junction (‘deletion band’) that would only amplify in the presence of deletion
36
. 
Biallelic deletion clones were identified as the absence of the non-deletion PCR band and 
the presence of the deletion PCR band. Inversion clones were identified as previously 
described by PCR
36
 (Supplementary Table 3). Briefly inversion clones had one inverted 
allele and one deleted allele without the presence of nondeletion alleles. In our experience 
biallelic inversion clones are very rare events
36
. PCR was performed using the Qiagen 
HotStarTaq 2× master mix and the following cycling conditions: 95°C for 15 minutes; 35 
cycles of 95°C for 15 seconds, 60°C for 1 minute, 72°C for 1 minute; 72°C for 10 minutes. 
Alternatively, PCR was also performed using 2× Accuprime Supermix II (Life 
Technologies) with the following cycling conditions: 94°C for 2 minutes; 35 cycles of 94°C 
for 20 seconds, 60°C for 20 seconds, 68°C for 1 min/kb of PCR product; 68°C for 5 
minutes. RNA was extracted from each positive clone using a kit (Qiagen) and quantitative 
real-time RTqPCR was performed using iQ SYBR Green Supermix (Bio-Rad). Primers used 
are found in Supplementary Table 5. Gene expression was normalized to that of GAPDH. 
We isolated four control, one BCL11A null, three composite enhancer deleted, one h+55 
deleted, one h+58 deleted, five h+62 deleted, three h+55 inverted, and two h+58 inverted 
clones. The BCL11A null clone had a 216 bp interstitial deletion of exon 2, preventing 
binding of the RT-qPCR primers. All gene expression data reported from these clones 
represents the mean of at least three technical replicates.
Design and synthesis of human and mouse lentiviral sgRNA libraries
Every 20-mer sequence upstream of an NGG or NAG PAM sequence on the plus or minus 
strand was identified for both the human and mouse orthologous +55, +58, and +62 DNase I 
hypersensitive site (DHS) as well as BCL11A/Bcl11a exon 2 (Extended Data). Relative to 
the human hg19 reference genome, a reference was used with the following substitutions to 
approximate a common low-HbF associated haplotype: rs1427407-G, rs1896293-T, 
rs6706648-T, rs6738440-G, rs7606173-C. The mouse orthologous sequences to each of the 
human DHSs were defined by using the liftOver tool of UCSC Genome Browser as 
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. Each of the sgRNA oligos were synthesized as previously 
described
25,51,52 and cloned using a Gibson Assembly master mix (New England Biolabs) 
into lentiGuide-Puro (Addgene plasmid ID 52963) which had been BsmBI digested, PCR 
purified, and dephosphorylated. Gibson Assembly products were transformed to 
electrocompetent cells (E. cloni, Lucigen). Sufficient colonies were isolated to ensure ∼90× 
library coverage for both human and mouse libraries. Plasmid libraries were deep sequenced 
to 533× and 813× coverage for human and mouse libraries respectively to confirm 
representation.
To produce lentivirus, HEK293T cells were cultured with Dulbecco's Modified Eagle's 
Medium (DMEM) (Life Technologies) supplemented with 10% fetal bovine serum (FBS) 
(Omega Scientific) and 2% penicillin-streptomycin (Life Technologies) in 15 cm tissue 
culture treated petri dishes. HEK293T were transfected at 80% confluence in 12 mL of 
media with 13.3 μg psPAX2, 6.7 μg VSV-G, and 20 μg of the lentiviral construct plasmid of 
interest using 180 μg of linear polyethylenimine (Polysciences). Medium was changed 16-24 
hours after transfection. Lentiviral supernatant was collected at 48 and 72 hours post-
transfection and subsequently concentrated by ultracentrifugation (24,000 rpm for 2 hours at 
4°C with Beckman Coulter SW 32 Ti rotor).
Tiled pooled CRISPR-Cas9 screen for in situ functional mapping the human BCL11A 
erythroid enhancer
HUDEP-2 cells with stable Cas9 expression were transduced at low multiplicity with the 
human sgRNA library lentivirus pool while in expansion medium. Control transductions 
were performed to ensure transduction rate did not exceed 50%. Cell numbers were 
maintained throughout the experiment at levels adequate to exceed 1000× representation of 
the library. 10 μg/mL blasticidin (Sigma) and 1 μg/mL puromycin (Sigma) were added 24 
hours after transduction to select for lentiviral library integrants in cells with Cas9. Cells 
were cultured in expansion media for one week followed by differentiation media for an 
additional week.
Intracellular staining was performed by fixing cells with 0.05% glutaraldehyde (grade II) 
(Sigma) for 10 minutes at room temperature. Cells were centrifuged for 5 minutes at 600 g 
and then resuspended in 0.1% Triton-X 100 (Life Technologies) for 5 minutes at room 
temperature for permeabilization. Triton X-100 was diluted with phosphate buffered saline 
(PBS) with 0.1% BSA and then centrifuged at 600 g for 15 minutes. Cells were stained with 
anti-human antibodies for HbF (clone HbF-1 with FITC or APC conjugation; Life 
Technologies) and β-hemoglobin antibody (clone 37-8 with PerCP-Cy5 or PE conjugation; 
Santa Cruz) for 20 minutes in the dark. Cells were washed to remove unbound antibody 
prior to FACS analysis. 0.2 μg HbF and 2 μg of HbA (β-hemoglobin) antibodies were used 
per 5 million cells. Control cells exposed to a nontargeting sgRNA sample and BCL11A 
exon 2 were used as negative and positive controls respectively to establish flow cytometry 
conditions. Populations of cells with the top and bottom 10% of expression of HbF were 
sorted by FACS.
After sorting the HbF-high and HbF-low pools, library preparation and deep sequencing was 
performed as previously described
25
. Briefly, genomic DNA was extracted using the Qiagen 
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Blood and Tissue kit. Herculase PCR reaction (Agilent) using lentiGuide-Puro specific 
primers (5′-AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG-3′ and 5′- 
CTTTAGTTTGTATGTCTGTTGCTATTATGTCTACTATTCTTTCCC-3′) including a 
handle sequence was performed as follows: Herculase II reaction buffer (1×), forward and 
reverse primers (0.5 μM each), dimethyl sulfoxide (DMSO) (8%), deoxynucleotide 
triphosphates (dNTPs) (0.25 mM each), Herculase II Fusion DNA Polymerase (0.5 
reactions) using the following cycling conditions: 95°C for 2 minutes; 20 cycles of 95°C for 
15 seconds, 60°C for 20 seconds, 72°C for 30 seconds; 72°C for 5 minutes. Multiple 
reactions of no more than 200 ng each were used to amplify from 6.6 ug gDNA (∼1e6 cell 
genomes) per pool. Samples were subjected to a second PCR using handle-specific 
primers
25
 to add adaptors and indexes to each sample using the following conditions: 
Herculase II reaction buffer (1×), forward and reverse primers (0.5 μM each), dNTPs (0.25 
mM each), Herculase II Fusion DNA Polymerase (0.5 reactions) with the following cycling 
conditions: 95°C for 2 minutes; 25 cycles of 95°C for 15 seconds, 60°C for 20 seconds, 
72°C for 30 seconds; 72°C for 5 minutes. PCR products were run on an agarose gel and the 
band of expected size was gel purified. Illumina MiSeq 150 bp paired end sequencing was 
performed.
sgRNA sequences present in the plasmid pool as well as in the HbF-high and HbF-low pools 
were enumerated. Guide sequences were mapped to the guides comprising the sgRNA 
library without allowing mismatches. Total reads were normalized to library sequencing 
depth. Cellular dropout score was determined by calculating (1) the ratio of normalized 
reads in the cells at end of experiment (average of reads in the HbF-high and HbF-low pools) 
to reads in the plasmid pool; (2) log2 transformation; and (3) median of biological replicates. 
HbF enrichment score was determined by calculating (1) the ratio of normalized reads in the 
HbF-high compared to reads in the HbF-low pools; (2) log2 transformation; and (3) median 
of biological replicates. After exclusion of sgRNAs with dropout scores < 2-3 and NAG 
PAM sgRNAs, a Q-Q plot was made with a line fitted through the first and third quantiles 
using R software. HbF enrichment scores and cellular dropout scores were compared by 
Spearman rank correlation. sgRNA sequences were mapped to the human genome (hg19) 
with cleavage positions set to between positions 17 and 18 given PAM positions 21-23. For 
visual comparisons to targeting sgRNAs, nontargeting sgRNAs were pseudomapped each 
separated by 5 bp.
Validation in primary human CD34+ hematopoietic stem and progenitor cells (HSPCs)
Primary human CD34+ HSPCs from G-CSF mobilized healthy adult donors were obtained 
from the Center of Excellence in Molecular Hematology at the Fred Hutchinson Cancer 
Research Center, Seattle, Washington. CD34+ HSPCs were subject to erythroid 
differentiation liquid culture as previously described
53
. Briefly, HSPCs were thawed on day 
0 into erythroid differentiation medium (EDM) consisting of IMDM supplemented with 330 
μg/mL holo-human transferrin, 10 μg/mL recombinant human insulin, 2 IU/mL heparin, 5% 
human solvent detergent pooled plasma AB, 3 IU/mL erythropoietin, 1% L-glutamine, and 
2% penicillin/streptomycin. During days 0-7 of culture, EDM was further supplemented 
with 10-6 M hydrocortisone (Sigma), 100 ng/mL human SCF, and human IL-3 (R&D). 
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During days 7-11 of culture, EDM was supplemented with 100 ng/mL human SCF only. 
During days 11-18 of culture, EDM had no additional supplements.
HSPCs were transduced with lentiCas9-Blast (Addgene plasmid ID 52962) 24 hours after 
thawing in the presence of 10 μM 16,16-dimethylprostaglandin E2 (PGE2; Cayman 
Chemical). At 48 hours after thawing, medium was changed and cells were transduced with 
lentiGuide-Puro or lentiGuide-Crimson cloned with relevant sgRNA sequence in the 
presence of 10 μM PGE2. Three independent transductions were performed per sgRNA. At 
72 hours after thawing, medium was changed and HSPCs were selected with 10 μg/mL 
blasticidin and 1 μg/mL puromycin or 10 μg/mL blasticidin followed by sorting for 
lentiGuide-Crimson+ cells on day 16 of culture. Blasticidin and/or puromycin selection 
occurred from days 3 to 8 of culture.
Differentiation was assessed on day 18 of culture using anti-human antibodies against the 
transferrin receptor (CD71) [Clone OKT9 with FITC conjugation; eBioscience] and 
glycophorin A (CD235a) [Clone HIR2 with PE conjugation; eBioscience]. Enucleation was 
assessed using 2 μg/mL of the cell-permeable DNA dye Hoescht 33342 (Life Technologies). 
CD235a+Hoescht 33342- cells were determined to be enucleated erythroid cells. Cells were 
intracellularly stained for HbF and HbA on day 18 of culture as described above. 
50,000-100,000 cells were centrifuged onto microscope slides at 350rpm for 4 minutes. 
Slides were stained with Harleco May-Grünwald stain (Millipore) for two minutes, Giemsa 
stain (Sigma) for 12 minutes, and two water washes for 30 seconds each. Slides were air 
dried and then cover-slipped using Fisher Chemical Permount Mounting Medium (Fisher). 
RNA isolation and RT-qPCR was performed as above. Gene expression was normalized to 
that of GAPDH. All gene expression data represents the mean of at least three technical 
replicates.
PCR primers were designed to amplify the genomic cleavage site for a given sgRNA. 
Resulting PCR products were subjected to Sanger sequencing. Sequencing traces were used 




Human erythroid H3K27ac ChIP-seq was obtained from Xu et al
7
 and mouse erythroid 
H3K27ac ChIP-seq was obtained from Kowalczyk et al
55
 and Dogan et al
56
. We uniformly 
processed all the datasets using the same pipeline with the same criteria to call super-
enhancers. Specifically, we started from raw reads and realigned each dataset with Bowtie2 
with the default parameters. We then removed duplicate reads with the Picard Suite. To call 
the peaks we used MACS2 in the narrow mode. Finally to call the super-enhancers we used 
the ROSE algorithm with the default parameters
10
. Using these settings, peaks closer than 
12.5 kb are stitched together and then ranked based on the H3K27ac intensity. To assign 
super-enhancers to genes we used again ROSE with default settings. In particular, the tool 
reports three categories of genes for each super-enhancer: 1) overlapping genes - genes for 
which the gene body region overlaps a super-enhancer; 2) proximal genes - genes close to a 
SE considering a window of 50kb; 3) closest gene - closest gene considering its TSS and the 
center of the super-enhancer. To generate a Venn diagram of genes for super-enhancer 
datasets, we used the union of these three gene categories.
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Hidden Markov Model (HMM) segmentation was performed to automatically segment the 
enrichment score signals into enhancer regions with Active, Repressive and Neutral effect. 
We designed a HMM with 3 states using the GHMM package (http://
ghmm.sourceforge.net/). To learn the HMM parameters we used the Baum-Welch algorithm. 
To find the best segmentation for each region we used the Viterbi algorithm. The emission 
probability for each state was modeled as a Gaussian distribution and all the possible 
transitions between states were allowed as shown in Extended Data Fig. 3a. Since the signal 
was not obtained with a constant genomic resolution, we interpolated and smoothed the 
signal using a Gaussian kernel over 12 bp and applied the HMM to the smoothed signal. To 
set the initial parameters, we used the 1%, 50% and 99% percentile of the smoothed signal 
for the prior of the means of the Repressive, Neutral and Active states respectively, while the 
prior for the standard deviation was set to 0.001 for all the three states.
Motif analysis was performed to evaluate the human and mouse enhancer regions for 
potential binding sites for known transcription factors (TFs). We used the FIMO software
57 
with a P-value threshold of < 10-4. For each region we extracted sequences using the hg19 
and mm9 assemblies respectively for human and mouse. The motif database was the latest 
version of the JASPAR database
58
.
Deep sequencing paired-end reads of genomic amplicons from genome editing target sites 
were first filtered for reads with PHRED quality score <30, merged with the FLASH (Fast 
Length Adjustment of SHort reads) software, and subsequently aligned to a reference 
amplicon using the needle aligner from the EMBOSS suite (http://emboss.sourceforge.net/) 
to quantify insertions and deletions. Per nucleotide frequency of deletion of a position, 
insertion directly adjacent to the position, or no mutation at the position was quantitated 
using CRISPResso (https://github.com/lucapinello/CRISPResso).
Pooled CRISPR-Cas9 screen for high resolution functional mapping of mouse Bcl11a 
enhancer
Murine erythroleukemia (MEL, MEL-745A cl. DS19) cells were cultured in DMEM 
supplemented with 10% FBS, 1% L-glutamine, and 2% penicillin-streptomycin as 
previously described
28,36. Cell lines tested negative for mycoplasma contamination. 
εy:mCherry reporter MEL cells with stable Cas9 expression were transduced at low 
multiplicity with the mouse sgRNA library lentivirus pool (Extended Data). Control 
transductions were performed to ensure transduction rate did not exceed 50%. Cell numbers 
were maintained throughout the experiment at levels adequate to exceed 1000× 
representation of the library. 10 μg/mL blasticidin and 1 μg/mL puromycin were added 24 
hours after transduction to select for lentiviral library integrants in cells with Cas9. 
Subsequently cells were cultured for two weeks. The top and bottom 5% of εy-mCherry-
expressing cells exposed to the library were sorted by FACS. A nontargeting sgRNA sample 
was used as a negative control and Bcl11a exon 2 as a positive control to establish flow 
cytometry conditions. After sorting, library preparation and deep sequencing were 
performed as described for the human library
25
.
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sgRNA sequences present in the Hbb-εy:mCherry-high and Hbb-εy:mCherry-low pools 
were enumerated. Cellular dropout and εy enrichment scores were calculated analogously to 
the human screen. sgRNA sequences were then mapped to the mouse genome (mm9).
Generation of genomic deletions in MEL cells
Deletions in MEL cells were generated using two sgRNA as previously described
36
. Briefly, 
sgRNA sequences were cloned into pX330 (Addgene plasmid ID 42230) using a Golden 
Gate assembly cloning strategy (Supplementary Table 1 and 4). MEL cells were 
electroporated with 5 μg of each pX330-sgRNA plasmid and 0.5 μg pmax-GFP (Lonza) in 
BTX electroporation buffer using a BTX electroporator (Harvard Apparatus). 
Approximately 48 hours post-electroporation, the top 1-3% of GFP+ cells were sorted and 
plated clonally at limiting dilution. Clones were allowed to grow for 7-10 days. Clones were 
screened for deletion by conventional PCR using the same strategy as with the HUDEP-2 
cells (Supplementary Table 2). Inversion clones were identified by PCR as previously 
described
36
 (Supplementary Table 3).
Generation of genomic deletions in mouse embryonic stem cells (mESCs)
mESCs were maintained on irradiated mouse embryonic fibroblasts (GlobalStem) and 
cultured in high glucose DMEM supplemented with 20% FBS, L-glutamine, penicillin/
streptomycin (Life Technologies), non-essential amino acids (Life Technologies), 
nucleosides, β-mercaptoethanol (Sigma), and leukemia inhibitory factor (Millipore). Cells 
were passaged using 0.25% trypsin (Life Technologies).
The Bcl11a +62 deletion mice were derived from CRISPR-Cas9 modified CJ9 ES cells. 
Using Amaxa ES Cell transfection reagent (Lonza), two million mESCs cells were 
electroporated with 2 μg of each pX330 plasmid vector containing individual target 
sequences flanking the +62 site along with 0.5 μg of a GFP plasmid. After 48 hours, the top 
5% of GFP expressing cells were sorted, plated on irradiated fibroblasts and maintained. 
Individual ES cell colonies were then picked and screened for biallelic deletion using the 
same strategy as HUDEP-2 and MEL cells
36
. DNA for screening CRISPR-Cas9 modified 
clones was obtained from gelatin adapted ES cell clones to avoid genomic contamination 
from the fibroblasts. Correctly targeted clones with greater than 80% normal karyotype were 
used to generate mice. Clones were injected into embryonic day 3.5 (E3.5) C57Bl6 
blastocysts and implanted into pseudo-pregnant females.
The β-YAC mouse line (A20), previously described as containing a transgene encompassing 
∼150 kb of the human β-globin locus
43
, was used to analyze human globin expression. The 
mouse line was maintained in a hemizygous state and bred with Bcl11a +62 deletion mice. 
Sufficient matings were established to ensure adequate homozygotes for analysis.
Mouse cell and tissue analysis
For developmental hematopoiesis, fetal liver cells were taken at E12.5, E14.5, E16.5, and 
E18.5 and mechanically dissociated to form single cell suspensions from which RNA was 
extracted using the RNeasy Plus Mini Kit (Qiagen) and analyzed. At E16.5, fetal liver were 
also stained with CD19-PerCP-Cy5.5 (Clone 1D3; eBioscience), B220-APC (RA3-6B2; 
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Biolegend), CD71-PE (Clone C2; BD Biosciences), and Ter119-FITC (Clone Ter119; BD 
Biosciences) to isolate B cells (B220+CD19+) and erythroid cells (Ter119+CD71+) by FACS 
for RNA extraction and BCL11A quantification. Additionally, flow cytometry was used to 
analyze fetal liver from E18.5 embryos. Single cell suspensions were stained with IgMFITC 
(Clone Il-41; eBioscience), CD19-PerCP-Cy5.5, (Clone 1D3; eBioscience), CD43-PE 
(Clone S7; eBioscience), AA4.1-PE-Cy7 (Clone AA4.1; BD Biosciences), B220-APC, 
(RA3-6B2; Biolegend), and DAPI (Invitrogen). For adult hematopoietic assays, peripheral 
blood was obtained from the tail vein of four week old male and female mice. Blood was 
collected in EDTA-coated tubes, red cells removed by 2% dextran (Sigma), residual red cells 
lysed with ammonium chloride solution (Stem Cell Technologies) and stained with the 
following anti-mouse antibodies: CD3e-FITC (Clone 145-2C11; Biolegend), CD19-PerCP-
Cy5.5 (Clone 1D3; eBioscience), CD71-PE (Clone C2; BD Biosciences), NK1.1-PE-Cy5 
(Clone PK136; Biolegend), Ter119-APC (Clone TER-119; Biolegend), Gr-1-eF450 (Clone 
RB6-8C5; eBioscience), B220-BV605 (RA3-6B2; Biolegend), Mac-1-BV510 (Clone 
M1/70; Biolegend), and 7-AAD (BD Biosciences). Fetal brain analysis was conducted on 
whole brains from E16.5 mouse embryos on ice cold PBS. Tissue was directly lysed into the 
RLT plus buffer (Qiagen) and total RNA extracted according to manufacturer's instructions 
provided in the RNeasy Plus Mini Kit. RT-qPCR performed as above, with gene expression 
normalized to Gapdh. All gene expression data represents the mean of at least three 
technical replicates. All animal experiments were conducted under the approval of the local 




 was PCR amplified to add BamHI-HF (5′) and EcoRI-HF (3′) restriction 
sites for cloning purposes using the following conditions: KOD buffer (1×), MgSO4 (1.5 
mM), dNTPs (0.2 mM each), forward primer (0.3 μM; 
GGCCGGCCggatccGGCGCAACAAACTTCTCTCTGCTGAAACAAGCCGGAGATGTC
GA AGAGAATCCTGGACCGATGGTGAGCAAGGGCGAGGA), reverse primer (0.3 μM; 
GGCCGGCCgaattcTTACTTGTACAGCTCGTCCA), and KOD Hot Start DNA Polymerase 
(0.02 U/μL) (Millipore). KOD PCR reaction used the following cycling conditions: 95°C for 
2 minutes; 50 cycles of 95°C for 20 seconds, 60°C for 20 seconds, and 70°C for 30 seconds; 
60°C for 5 minutes. PCR products were purified (QIAquick PCR Purification Kit, Qiagen) 
and blunt end cloned with Zero Blunt PCR cloning kit (Invitrogen). PCR-blunt cloned 
products and lentiCas9-Blast (Addgene plasmid ID 52962) were separately digested with 
BamHI-HF (New England Biolabs) and EcoRI-HF (New England Biolabs) in 1× Buffer 
CutSmart at 37°C (New England Biolabs). Digest of lentiCas9-Blast was performed to 
remove the blasticidin cassette. Then digested PCR product was ligated into the lentiCas9 
backbone.
Cloning lentiGuide-Crimson
E2-Crimson template (Clontech) was PCR amplified to add BsiWI (5′) and MluI (3′) 
restriction sites for cloning purposes using the following conditions: KOD buffer (1×), 
MgSO4 (1.5 mM), dNTPs (0.2 mM each), forward primer (0.3 μM; 
GGCCGGCCCGTACGcgtacgGCCACCATGGATAGCACTGAGAACGTCATCAAGCCCT
T), reverse primer (0.3 μM; 
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GGCCGGCCacgcgtCTACTGGAACAGGTGGTGGCGGGCCT), and KOD Hot Start DNA 
Polymerase (0.02 U/μL). KOD PCR reaction used the following cycling conditions: 95°C 
for 2 minutes; 50 cycles of 95°C for 20 seconds, 60°C for 20 seconds, and 70°C for 30 
seconds; 60°C for 5 minutes. PCR products were purified (QIAquick PCR Purification Kit) 
and cloned with Zero Blunt PCR cloning kit. Cloned products and lentiGuide-puro were 
separately digested with BsiWI (New England Biolabs) and MluI (New England Biolabs) in 
1× Buffer 3.1 at 37°C (New England Biolabs). Digest of lentiGuide-Puro (Addgene plasmid 
ID 52963) was performed to remove the puromycin cassette. Then digested PCR product 
was ligated into the lentiGuide backbone.
Cloning sgRNAs
lentiGuide-Puro (Addgene plasmid ID 52963) was digested with BsmBI in 1× Buffer 3.1 at 
37°C (New England Biolabs) for linearization. One unit of TSAP thermosensitive Alkaline 
Phosphatase (Promega) was added for 1 hour at 37°C to dephosphorylate the linearized 
lentiGuide and then TSAP was heat inactivated at 74°C for 15 minutes. Linearized and 
dephosphorylated lentiGuide was run on an agarose gel and gel purified. sgRNA-specifying 
oligos were phosphorylated and annealed using the following conditions: sgRNA sequence 
oligo (10 μM); sgRNA sequence reverse complement oligo (10 μM); T4 ligation buffer (1×) 
(New England Biolabs); and T4 polynucleotide kinase (5 units) (New England Biolabs) with 
the following temperature conditions: 37 °C for 30 min; 95 °C for 5 min; and then ramp 
down to 25 °C at 5 °C/min. Annealed oligos were ligated into lentiGuide in a 1:3 ratio 
(vector:insert) using T4 ligation buffer (1×) and T4 DNA Ligase (750 Units) (New England 
Biolabs. Plasmids were verified by sequencing using a U6F promoter forward primer 
CGTAACTTGAAAGTATTTCGATTTCTTGGC.
sgRNA-specifying oligos using sgRNA sequences from the screen library (Extended Data) 
were obtained and cloned as described into either lentiGuide-Puro or lentiGuide-Crimson. 
sgRNA constructs were used to produce lentivirus and transduce HUDEP-2 with stable Cas9 
expression. Bulk cultures were incubated for 7-10 days with 10 μg/mL blasticidin and 1 
μg/mL puromycin selection to allow for editing. Then bulk cultures were plated clonally at 
limiting dilution. Clones were allowed to grow for approximately 14 days and then genomic 
DNA was extracted using 50 μL QuickExtract DNA Extraction Solution per well.
lentiTandemGuide cloning
lentiGuide-sgRNA1 was digested with PspXI and XmaI at 37°C for four hours (New 
England Biolabs). Digests were run on an agarose gel and gel purified. lentiGuide-sgRNA2 
was linearized using NotI (New England Biolabs). The hU6 promoter and sgRNA chimeric 
backbone for lentiGuide-sgRNA2 was PCR amplified using the following conditions: KOD 
buffer (1×), MgSO4 (1.5 mM), dNTPs (0.2 mM each), forward primer (0.3 μM; 
GGCCGGCCgctcgaggGAGGGCCTATTTCC), reverse primer (0.3 μM; 
CCGGCCGGcccgggTTGTGGATGAATACTGCCATTT), and KOD Hot Start DNA 
Polymerase (0.02 U/μL) (Millipore). KOD PCR reaction used the following cycling 
conditions: 95°C for 2 minutes; 50 cycles of 95°C for 20 seconds, 60°C for 20 seconds, and 
70°C for 30 seconds; 60°C for 5 minutes. PCR products were purified (QIAquick PCR 
Purification Kit), blunt ended cloned with Zero Blunt PCR cloning kit, transformed, and 
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plated. Colonies were screened by digesting minipreps with EcoRI. Mini-preps were then 
digested with PspXI and XmaI as described above followed by PCR purification. Following 
PCR purification, sgRNA2 was ligated into digested lentiGuide-sgRNA1. Sequence verified 
with following primers: GGAGGCTTGGTAGGTTTAAGAA and 
CCAATTCCCACTCCTTTCAA.
Generation of HUDEP-2 with stable Cas9
lentiCas9-Blast (Addgene plasmid ID 52962) or lentiCas9-Venus were produced as 
described above and used to transduce HUDEP-2 cells. Transduced cells were selected with 
10 μg/mL blasticidin or Venus+ cells were sorted. Functional Cas9 was confirmed using the 
pXPR-011 (Addgene plasmid ID 59702) GFP reporter assay as previously described
60
.
Generation of εy:mCherry reporter MEL cells
A reporter MEL line in which mCherry was been knocked into the Hbb-y locus was created 
(Extended Data Figure 5a). Briefly, a TALEN-induced DSB was created adjacent to the 
Hbb-y transcriptional start site. A targeting vector with mCherry and a neomycin cassette 
were introduced through homology directed repair. Homology arms included mm9 
sequences from chr7:111,001,667-111,002,675 and chr7:111,000,661-111,001,666. Cre-
mediated recombination was utilized to remove the neomycin cassette. Long-range PCR 
spanning each homology arm was utilized to ensure appropriate targeted integration. Cells 
were tested upon Bcl11a disruption by RT-qPCR and flow cytometry to confirm expected 
effects on εy:mCherry derepression. Subsequently CRISPR-Cas9 was used as described 
above to produce cells with monoallelic composite enhancer deletion to maximize screening 
sensitivity for enhancer disruption.
Generation of MEL cells with stable Cas9 expression
lentiCas9-Blast (Addgene plasmid ID 52962) lentivirus were produced as described above 
and used to transduce MEL cells. Transduced cells were selected with 10 μg/mL blasticidin. 
Functional Cas9 was confirmed using the pXPR-011 (Addgene plasmid ID 59702) GFP 




Extended Data Figure 1. Human BCL11A locus
a, Schematic of the human BCL11A locus (hg19, transcription from right to left) with 
erythroid chromatin marks and trait-associated haplotype denoted, and composite enhancer 
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. b, Ranked enhancers in primary human adult erythroid precursors 
by H3K27ac signal intensity, with super-enhancers shaded, and super-enhancer associated 
genes indicated.
Extended Data Figure 2. Tiled pooled in situ CRISPR-Cas9 BCL11A enhancer screen
a, Distribution of NGG and NAG PAM sgRNAs mapped to genomic cleavage position. The 
vertical lines represent cleavage sites for sgRNAs mapped to plus and minus strands. b, Gap 
distance between adjacent genomic cleavage position for NAG PAM sgRNAs. c, Library 
composition by target sequence and PAM restriction. d. Representation of both NGG and 
NAG sgRNA (1,338 sgRNAs in total) within the plasmid pool by deep-sequencing. The 
median was 718 normalized reads and the 10th and 90th percentiles (indicated by the 
vertical dotted lines) ranged from 337 to 1,205 normalized reads. e, HbF distribution in 
HUDEP-2 cells transduced with Cas9 and individual sgRNAs, either nontargeting or 
targeting BCL11A exon 2. f, HbF enrichment scores of NGG sgRNAs in six biological 
replicates. g, Sort of library-transduced cells into HbF-high and HbF-low pools. h, Control 
sgRNA enrichment. Boxes demonstrate 25th, median, and 75th percentiles and whiskers 
minimum and maximum values. **** P < 0.0001, ns non-significant. i, NGG sgRNA 
representation in plasmid pool and cells at conclusion of experiment (left), and in HbF-high 
and HbF-low pools (right), with dotted lines at x=y and x=8y. j, Quantile-quantile plots of 
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NGG sgRNA enrichment scores. k, Cellular dropout scores of NGG sgRNAs relative to 
genomic cleavage position and repetitive elements. Nontargeting sgRNAs pseudo-mapped 
with 5 bp spacing.
Extended Data Figure 3. Validation of enhancer screen
a, HbF+ fraction in HUDEP-2 cells transduced in arrayed format with 24 sgRNAs from all 5 
mapping categories with enrichment scores ranging from the highest to the lowest in the 
screen. b, Correlation between HbF enrichment score from pooled sgRNA screen and HbF+ 
fraction by arrayed validation of individual sgRNAs in HUDEP-2 cells. c, Erythroid 
differentiation of primary human erythroid precursors evaluated by CD71 and CD235a 
surface markers, enucleation frequency (CD235a+ Hoescht33342-), and morphology by 
May-Grünwald-Giemsa staining.
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Extended Data Figure 4. Functional assessment of enhancer sequences
a, Topology of the Hidden Markov model (HMM) used to infer the three functional 
enhancer states (Active, Repressive, and Neutral). The emission probabilities of HbF 
enrichment scores from each state were modeled as Gaussian distributions (the values of μ 
and σ2 are shown). The transition probabilities (arrows) are displayed. b, Frequency 
distribution of indels from HUDEP-2 cells exposed to Cas9 and individual sgRNAs, sorted 
into HbF-high and -low pools, and subjected to deep sequencing of the target site. Indels 
calculated on a per nucleotide basis throughout an amplicon surrounding the sgRNA-1617 
and -1621 cleavage sites (dotted lines). An indel enrichment ratio was calculated by dividing 
normalized indel frequencies in the HbF-high pool by those in the HbF-low pool.
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Extended Data Figure 5. Functional cores of the BCL11A enhancer
a-c, 200 bps at the functional cores of DHSs h+55, h+58, and h+62 defined by HMM states 
(Active red, Repressive green). HbF enrichment scores shown by gray lines and circles. HbF 
indel enrichment per nucleotide based on amplicon genomic sequencing of sorted cells 
exposed to either sgRNA-1617 (top) or -1621 (bottom). Common SNPs (MAF>1%) shown 
with dotted lines with HbF-low allele in blue and HbF-high allele in red; no common SNPs 
present at h+58 region. JASPAR motifs (P < 10-4) depicted in black except for those with 
allele-specific significance depicted by allelic color. Selected motifs annotated by TF based 
on known erythroid-specific function or genomic position. Motif LOGOs at key positions 
with motif scores P < 10-3 as described in text. Dotted boxes show regions of highest HbF 
enrichment score at each core with underlying predicted motifs. Orthologous sequences 
listed from representative primates and nonprimates of distributed phylogeny. PhyloP (scale 
from -4.5 to 4.88) and PhastCons (from 0 to 1) estimates of evolutionary conservation 
among 100 vertebrates. An arrow indicates a 144 bp insertion in the mouse genome relative 
to the human reference adjacent to the orthologous GATA1 motif at h+58.
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Extended Data Figure 6. Tiled pooled in situ CRISPR-Cas9 Bcl11a enhancer screen
a, Schematic of the mouse Bcl11a locus (mm9, transcription from left to right) with 
erythroid chromatin marks (top, dark blue H3K27ac from Kowalczyk et al
55
, middle, light 
blue H3K27ac from Dogan et al
56
, and bottom, black DNase I from Bauer et al
28
) and 
regions of primary sequence homology to the human DHSs displayed. Y-axes for H3K27ac 
tracks are both scaled to maximum 3.5 reads per million. Composite enhancer as previously 
defined
28
. b, Ranked enhancers in mouse erythroid precursors by H3K27ac signal 
intensity
55,56, with super-enhancers shaded. Super-enhancer associated genes indicated by 
Venn diagram. c, Strategy to knock-in by homology-directed repair the fluorescent protein 
mCherry into the mouse embryonic globin Hbb-y locus (encoding the εy embryonic globin 
chain). d, Distribution of NGG and NAG PAM sgRNAs mapped to genomic cleavage 
position with vertical lines representing cleavage sites for sgRNAs mapped to plus and 
minus strands. e, Distance to adjacent genomic cleavage position for NGG (left) and NAG 
(right) PAM sgRNAs. f, Representation of the 1,271 NGG and NAG sgRNAs within the 
plasmid pool by deep-sequencing. The median was 735 normalized reads and the 10th and 
90th percentiles (indicated by the vertical dotted lines) ranged from 393 to 1,240 normalized 
reads. g, Library composition by target sequence and PAM restriction. h, mCherry 
expression upon exposure to Cas9 and an individual NGG sgRNA targeting Bcl11a exon 2 
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in MEL εy:mCherry reporter cells. i, εy:mCherry sort of library transduced cells. j, Control 
sgRNA enrichment. Boxes demonstrate 25th, median, and 75th percentiles and whiskers 
minimum and maximum values. **** P < 0.0001. k, Enrichment scores of NGG sgRNAs 
between four biological replicates.
Extended Data Figure 7. Bcl11a enhancer screen analyses
a, NGG sgRNA representation in plasmid pool and cells at conclusion of experiment (left), 
and in εy:mCherry-high and εy:mCherry-low pools (right), with dotted lines at x=y and 
x=8y. b, Quantile-quantile plots of NGG sgRNA εy enrichment scores. c, Cellular dropout 
scores of NGG sgRNAs relative to genomic cleavage position and repetitive elements. 
Nontargeting sgRNAs pseudo-mapped with 5 bp spacing. d, Correlation between cellular 
dropout and εy enrichment scores.
Canver et al. Page 24













Extended Data Figure 8. Functional sequences at the Bcl11a erythroid enhancer
a-c, HMM segmentation of active functional states at m+55, m+58, and m+62 orthologs. 
HbF enrichment scores shown as gray lines and circles with blue line representing smoothed 
enrichment score. DNase I sequencing from mouse fetal liver erythroid precursors
28
. PhyloP 
(scale from -3.3 to 2.1) and PhastCons (from 0 to 1) estimates of evolutionary conservation 
among 30 vertebrates. d, Top, BCL11A expression determined by RT-qPCR displayed as a 
heatmap in 108 hemizygous m+62 ortholog deletion clones ordered by genomic position of 
deletion midpoint. Each bar demonstrates the genomic position of the deletion breakpoints 
and the associated color demonstrates the level of BCL11A expression. Bottom, BCL11A 
expression determined by RT-qPCR in 108 hemizygous m+62 ortholog deletion clones. Per 
nucleotide mean effect size was calculated as the mean fold change in BCL11A expression 
from all clones in which that nucleotide was deleted. Gray shading represents one s.d. The 
BCL11A expression data are shown with same x-axis as in Extended Data Fig. 8c 
immediately above.
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Extended Data Figure 9. Evaluation of the m+62 functional core
200 bp at the functional core of the m+62 ortholog defined by HMM state. Enrichment 
scores shown as gray lines and circles with blue line representing smoothed enrichment 
score. JASPAR motifs (P < 10-4) depicted with selected motifs annotated by TF name based 
on known erythroid-specific function or genomic position. Orthologous human sequences 
listed. PhyloP (scale from -3.3 to 2.1) and PhastCons (from 0 to 1) estimates of evolutionary 
conservation among 30 vertebrates. Individual numbered hemizygous deletion clones with 
indicated breakpoints were evaluated by BCL11A immunoblot (C, control). Clones 9 and 10 
encompass the entire m+62 ortholog.
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Extended Data Figure 10. Requirement of Bcl11a erythroid enhancer during murine ontogeny
a, Progeny of heterozygous Bcl11a m+62 ortholog deletion intercrosses as compared to 
expected Mendelian ratio. b, Fraction of fetal liver comprised of B cell progenitors at E16.5 
from various genotypes. c, Peripheral blood analysis from 4 week old mice to examine the 
frequency of various circulating hematopoietic lineages in Bcl11a m+62 ortholog deletion 
wild-type, heterozygous, and homozygous mice. d, BCL11A expression in β-YAC/+62 
deletion mice (each symbol represents the mean expression from technical replicates from 
an individual mouse). * P < 0.05, error bars represent s.e.m.
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Figure 1. Tiled pooled in situ CRISPR-Cas9 BCL11A enhancer screen
a-c, Deletion of the human composite BCL11A enhancer in HUDEP-2 cells demonstrates its 
necessity for BCL11A expression (normalized to GAPDH), repression of γ-globin mRNA, 
and repression of HbF; control clones, n = 4; BCL11A null, n = 1; enhancer deleted, n = 3; 
error bars show s.e.m. d, Workflow of CRISPR-Cas9 enhancer screen showing library 
synthesis, delivery, and analysis. e, Human NGG PAM sgRNA library distribution. f, Gaps 
between adjacent genomic cleavages for NGG PAM sgRNAs targeting BCL11A exon-2, h
+55, h+58, and h+62.
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Figure 2. Functional mapping of the BCL11A enhancer
a, Mapping sgRNA HbF enrichment scores relative to genomic cleavage positions. 
Nontargeting sgRNAs pseudo-mapped with 5 bp spacing. b, Correlation between cellular 
dropout and HbF enrichment scores. c-e, BCL11A expression normalized to GAPDH, β-like 
globin expression, and HbF+ fraction in HUDEP-2 cells with deletion or inversion of 
individual DHSs; control clones, n = 4; enhancer deleted, n = 3; +55 deleted, n = 1; +58 
deleted, n = 1; +62 deleted, n = 5; +55 inverted, n = 3; +58 inverted, n = 2. f-h, BCL11A 
expression normalized to GAPDH, β-like globin expression, and HbF+ fraction in primary 
human erythroid precursors transduced with Cas9 and individual sgRNAs; n = 3. Error bars 
represent s.e.m. (c, d, f, g) or s.d. (e, h).
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Figure 3. Inferred functional enhancer states relative to genomic features
a-c, Hidden Markov model segmentation of functional enhancer states. HbF enrichment 
scores shown throughout DHSs h+55, h+58, h+62 by gray lines and circles with blue line 
representing smoothed enrichment score. DNase I sequencing from primary human 
erythroblasts
28
. PhyloP (scale from -4.5 to 4.88) and PhastCons (from 0 to 1) estimates of 
evolutionary conservation among 100 vertebrates. Positions of SNPs rs7606173 and 
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Figure 4. Primate-specific BCL11A enhancer functional core
DHS h+58 functional core defined by maximal HbF enrichment score and Active HMM 
state. HbF enrichment scores shown by gray lines and circles. HbF indel enrichment per 
nucleotide based on amplicon genomic sequencing of sorted cells exposed to either 
sgRNA-1617 or -1621. No common SNPs (MAF>1%) present at this region. JASPAR 
motifs (P < 10-4) depicted in black with selected motifs annotated by TF based on known 
erythroid-specific function or genomic position. Gata1 motif LOGO at sgRNA-1617 
cleavage position as described in text. Orthologous sequences listed from representative 
primates and nonprimates of distributed phylogeny. PhyloP (scale from -4.5 to 4.88) and 
PhastCons (from 0 to 1) estimates of evolutionary conservation among 100 vertebrates.
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Figure 5. Functional sequence requirement at the mouse Bcl11a erythroid enhancer for in vivo 
hemoglobin switching
a, Mapping sgRNA εy enrichment scores to genomic cleavage positions. Nontargeting 
sgRNAs pseudo-mapped with 5 bp spacing. b, BCL11A expression in mouse erythroid 
clones with deletion or inversion of individual DHSs relative to nondeleted controls. c, 
Transgenic human β-like globin expression in β-YAC/+62 deletion mice. For +/+, +/Δ, and 
Δ/Δ: at E12.5, n = 5, 11, and 3 embryos respectively; at E14.5, n = 2, 3, and 4; at E16.5, n = 
2, 4, and 1; at E18.5, n = 3, 1, and 3. Error bars represent s.e.m.
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